Aerie Pharmaceuticals Inc., of Bedminster, N.J., appointed Marvin J. Garrett vice president, regulatory affairs and quality assurance.

Alchemia Ltd., of Brisbane, Australia, appointed Thomas Liquard CEO.

Alcobra Ltd., of Tel Aviv, Israel, named Tomer Berkovitz chief financial officer, effective May 1.

Amag Pharmaceuticals Inc., of Waltham, Mass., named Edward Jordan senior vice president of sales and marketing.

Amarantus Bioscience Holdings Inc., of San Francisco, appointed Kerry Segal head of business development, and Tiffini Clark head of regulatory affairs.

Ambrx Inc., of La Jolla, Calif., added Sheila Gujrathi to its board.

Biolinerx Ltd., of Jerusalem, appointed Sandra Panem to its board.

Cynapsus Therapeutics Inc., of Toronto, added Nan Hutchinson to its board.

Gliknik Inc., of Baltimore, named Jeffrey Herpst senior director, clinical development, and elected Mark Lerner and Richard Levy to its board.

Immunogen Inc., of Waltham, Mass., named Ellie Harrison chief human resources officer.

Imprimis Pharmaceuticals Inc., of San Diego, appointed Randle House vice president of pharmacy operations.

Inovio Pharmaceuticals Inc., of Blue Bell, Pa., appointed Laurent Humeau vice president of R&D, and Jan Marie-Albert Van Tornout vice president of clinical development.

Intercept Pharmaceuticals Inc., of New York, appointed Sanj K. Patel and Glenn Sblendorio to its board.

Iroko Pharmaceuticals LLC, of Philadelphia, appointed Bradley T. Sheares and Louis Vollmer to its board.

Ironwood Pharmaceuticals Inc., of Cambridge, Mass., added Julie McHugh to its board.

Otonomy Inc., of San Diego., appointed Robert Savel chief technical officer.

PDL Biopharma Inc., of Incline Village, Nev., named Stephen J. Hoffman senior advisor.

Phosphagenics Ltd., of Melbourne, Australia, appointed Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh nonexecutive directors of the board; Gozlan was named chairman on an interim basis.

PTC Therapeutics Inc., of South Plainfield, N.J., named Guido Schopen general manager and head of medical affairs for Europe.

Ventria Bioscience Inc., of Fort Collins, Colo., appointed Seymour Fein chief medical officer.

Virobay Inc., of Menlo Park, Calif., appointed Thomas J. Dietz to its board.

Wuxi Pharmatech Inc., of Shanghai, appointed Hua Mu senior vice president of operations and global head of the product development service and partnership business unit.